Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)

Objective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 µg/day fluocinolone acetonide [FAc] intravitreal implant (ILUVIEN(®)) in patients with persistent or recurrent diabetic macular edema (DME) and 6–18 months of follow-up. Methods: Retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: McCluskey, Jessica D, Kaufman, Paul L, Wynne, Kathy, Lewis, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489583/
https://www.ncbi.nlm.nih.gov/pubmed/31114396
http://dx.doi.org/10.2147/IMCRJ.S191171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489583/
https://www.ncbi.nlm.nih.gov/pubmed/31114396
http://dx.doi.org/10.2147/IMCRJ.S191171

Ejemplares similares